慢性基础肝病对新型冠状病毒肺炎患者结局的影响*

doi:10.3969/j.issn.1672-5069.2022.06.037

Abstract

Abstract: Objective Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection leads to a new type of coronavirus disease (COVID-19), which is still rampant in the world. It is reported that about 2% to 11% of SARS-CoV-2 infected patients have underlying chronic liver disease, and the impact of liver diseases on the susceptibility and severity of patients with COVID-19 infection, and whether the SARS-CoV-2 infection will deteriorate the progression of chronic liver diseases is still unclear. In this article, we mainly focus on the influence of different basic liver diseases on the outcomes of patients with COVID-19 infection.

Key words: Coronavirus disease 2019, Chronic liver disease, Liver injury, Prognosis

Cui Po, Dong Shiming, Nan Yuemin. Prognosis of COVID-19 patients with underlying chronic liver diseases[J]. Journal of Practical Hepatology, 2022, 25(6): 905-908.

References

[1] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges.Lancet Gastroenterol Hepatol, 2020, 5: 428-430.
[2] Guan WJ, Ni ZY, Hu Y,et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18):1708-1720.
[3] 胡利琳, 王玮珺, 朱清静, 等. 新型冠状病毒肺炎相关肝损伤:病因分析及治疗策略. 中华肝脏病杂志, 2020,25(2): 97-99.
[4] Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol,2020, 33(6):1007-1014.
[5] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8(4):420-422.
[6] Lei F, Liu YM, Zhou F, et al. Longitudinalassociation between markers of liver injury and mortality in COVID-19 in China. Hepatology, 2020, 72: 389-398.
[7] Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study. Hepatol Int, 2020, 14: 690-700.
[8] Marjot T, Webb GJ, Barritt ASt, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol, 2020, 18: 348-364.
[9] Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med, 2020, 382: 2137-2145.
[10] Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol, 2021, 74: 567-577.
[11] Satapathy SK, Roth NC, Kvasnovsky C, et al. Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study. Hepatol Int, 2021,15:300-304.
[12] Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut, 2021, 70: 531-536.
[13] Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol, 2021, 73: 1063-1071.
[14] Liu R, Zhao L, Cheng X, et al. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int, 2021, 41: 720-730.
[15] Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212: 416-420.
[16] Lens S, Miquel M, Mateos-Munoz B, et al. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. J Hepatol, 2020, 73: 1262-1263.
[17] Elfiky AA. Ribavirin,remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci, 2020, 253: 117592.
[18] Chen L, Huang S, Yang J, et al. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. J Viral Hepat, 2020, 27: 1504-1507.
[19] Lin Y, Yuan J, Long Q, et al. Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. GeneDis, 2021, 8: 484-492.
[20] Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. World J Gastroenterol, 2021, 27: 782-793.
[21] Zou X, Fang M, Li S, et al. Characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Clin Gastroenterol Hepatol, 2021, 19: 597-603.
[22] Wong GL, Wong VW, Yuen BW, et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol, 2020, 72: 57-66.
[23] Liu J, Wang T, Cai Q, et al. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol Res, 2020, 50: 1211-1221.
[24] Rodriguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat, 2021, 28: 89-94.
[25] Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep, 2020, 2: 100113.
[26] Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology, 2020, 72: 287-304.
[27] Force AC-T, Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int, 2020, 14: 415-428.
[28] Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol, 2020, 73: 451-453.
[29] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181: 271-280,e278.
[30] Singh MK, Mobeen A, Chandra A, et al. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med, 2020, 130: 104219.
[31] Fondevila MF, Mercado-Gómez M, Rodríguez A, et al. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. J Hepatol, 2021, 74: 469-471.
[32] Zheng KI, Gao F, Wang XB, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism, 2020, 108: 154244.
[33] Dongiovanni P, Meroni M, Longo M, et al. MAFLD in COVID-19 patients: an insidious enemy. Expert Rev Gastroenterol Hepatol, 2020, 14: 867-872.
[34] Portincasa P, Krawczyk M, Smyk W, et al. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest, 2020, 50: e13338.
[35] Praveen S, Ashish K, Anikhindi SA, et al. Effect of COVID-19 on pre-existing liver disease: What Hepatologist should know? J Clin Exp Hepatol, 2020,35:124-128.
[36] Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut, 2020, 69: 1545-1547.
[37] Roca-Fernández A, Dennis A, Nicholls R, et al. Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19. Front Med, 2021, 8: 636637.
[38] Campos-Murguia A, Roman-Calleja BM, Toledo-Coronado IV, et al. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis, 2021,85:282-291.
[39] Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int, 2020, 40: 2568.
[40] Di Giorgio A, Nicastro E, Speziani C, et al. Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. J Hepatol, 2020, 73: 702-705.
[41] Verhelst X, Somers N, Geerts A, et al. Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. J Hepatol, 2021, 74: 240-241.
[42] Marjot T, Buescher G, Sebode M, et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol, 2021,15:327-330.
[43] Efe C, Dhanasekaran R, Lammert C, et al. Outcome of COVID-19 in patients with autoimmune hepatitis: an international multi-centre study. Hepatology, 2021,45:123-127.
[44] Sung H, Ferlay J, Siegel RL, et al. Globalcancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
[45] Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol, 2020, 21: 335-337.
[46] 易滨, 张磊, 袁振刚, 等. 新型冠状病毒肺炎疫情下肝癌的诊断与治疗策略. 肝胆外科杂志, 2020, 28(3): 208-212.

Prognosis of COVID-19 patients with underlying chronic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhao Zide, Wu Lingjie, Zhang Haisheng, et al.. Could the supplement of human blood albumin product reduce the incidence of drug-induced liver injury in patients with pulmonary tuberculosis and hypoproteinemia? [J]. Journal of Practical Hepatology, 2022, 25(6): 792-795.
[2]	Li Rong, Cao Jingjing, Li Jing, et al.. Triggering and impacting factors of prognosis in patients with hepatitis B virus-associated acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2022, 25(6): 832-835.
[3]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[4]	Shi Qingchun, Pan Limin, Bu Fan, et al.. TCGA-based study of cell necrosis-related genes as prognostic indicators in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(6): 869-872.
[5]	Gao Zhengxing, Li Guangxin, Song Chunqing. Prognosis of patients with hepatocellular carcinoma after hepatectomy and sorafenib therapy: prediction by cancerous M6A methyltransferase-like protein 3 levels [J]. Journal of Practical Hepatology, 2022, 25(6): 885-888.
[6]	Wang Qian, Li Wenli, Wang Bing, et al.. Clinical characteristics of patients with Dengue fever: A report of 70 cases [J]. Journal of Practical Hepatology, 2022, 25(5): 645-648.
[7]	Liu Yan, Shen Yu,Zhang Qian. Characteristics and clinical outcomes of 60 patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(5): 649-652.
[8]	Wang Mingqiang, Niu Yaofei, Wang Shengfeng. Serum clusterin levels in patients with hepatitis B virus-related acute-on-chronic liver failure and its correlation with short-term prognosis [J]. Journal of Practical Hepatology, 2022, 25(5): 677-680.
[9]	Jiang Lina, Tian Hui, Yuan Zhijun, et al.. Prognosis of patients with gallbladder cancer by serum vascular endothelial growth factor C levels [J]. Journal of Practical Hepatology, 2022, 25(5): 746-749.
[10]	Liu Haitao, Zhang Leiming, Li Jingwei. Clinical and pathological features in patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(4): 508-511.
[11]	Fu Lihong, Gao Yueqiu, Wang XiaoLin, et al. Liver pathological features of patients with drug-induced liver injury: An analysis of 38 cases [J]. Journal of Practical Hepatology, 2022, 25(4): 512-516.
[12]	Chen Yejing, Lu Qingping, Gu Shaoying. Comparison of therapeutic efficacy of magnesium isoglycyrrhizinate and compound glycyrrhizin monoamine in treatment of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(3): 371-374.
[13]	Sun Yanan, Zeng Qinghuan, Liu Yuanzhi, et al. Influencing factors for prognosis of patients with acute-on-chronic liver failure and moderate or severe esophageal varices [J]. Journal of Practical Hepatology, 2022, 25(3): 391-394.
[14]	Hu Lingxi, Cui Po, Wang Rongqi. Liver injuries in patients with corona virus disease 2019 [J]. Journal of Practical Hepatology, 2022, 25(3): 453-456.
[15]	Liu Shangzhi, Zhang Zhiqiang, Li Shengjin. Protective mechanism of Danzhi Xiaoyao powder on hepatic damage in rats with D-galactosamine/lipopolysaccharides-induced acute liver injury [J]. Journal of Practical Hepatology, 2022, 25(2): 179-182.